{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:55Z","timestamp":1792113235314,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02219-w","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T05:02:37Z","timestamp":1658206957000},"page":"3979-4002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T\u00a0Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings"],"prefix":"10.1007","volume":"39","author":[{"given":"Ulrike","family":"Wehkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ardig\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2219_CR1","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv30\u201340.","journal-title":"Ann Oncol"},{"key":"2219_CR2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314.","journal-title":"Blood"},{"key":"2219_CR3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","volume":"371","author":"ST Hwang","year":"2008","unstructured":"Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and S\u00e9zary syndrome. Lancet. 2008;371:945\u201357.","journal-title":"Lancet"},{"key":"2219_CR4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/leu.2011.237","volume":"26","author":"T Krejsgaard","year":"2012","unstructured":"Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A. Regulatory T\u00a0cells and immunodeficiency in mycosis fungoides and S\u00e9zary syndrome. Leukemia. 2012;26:424\u201332.","journal-title":"Leukemia"},{"key":"2219_CR5","doi-asserted-by":"crossref","unstructured":"Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T\u00a0cell lymphoma. J Clin Invest. 2005;115:798\u2013812. Erratum in: J Clin Invest. 2007;117:836.","DOI":"10.1172\/JCI24826"},{"key":"2219_CR6","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","volume":"350","author":"M Girardi","year":"2004","unstructured":"Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978\u201388.","journal-title":"N Engl J Med"},{"key":"2219_CR7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.pas.0000153121.57515.c6","volume":"29","author":"C Massone","year":"2005","unstructured":"Massone C, Kodama K, Kerl H, Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol. 2005;29:550\u201360.","journal-title":"Am J Surg Pathol"},{"key":"2219_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2015.04.030","volume":"73","author":"KE Sufficool","year":"2015","unstructured":"Sufficool KE, Lockwood CM, Abel HJ, et al. T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. J Am Acad Dermatol. 2015;73:228-36.e2.","journal-title":"J Am Acad Dermatol"},{"key":"2219_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12308-015-0247-2","volume":"8","author":"NT Harvey","year":"2015","unstructured":"Harvey NT, Spagnolo DV, Wood BA. \u2018Could it be mycosis fungoides?\u2019: an approach to diagnosing patch stage mycosis fungoides. J Hematopathol. 2015;8:209\u201323.","journal-title":"J Hematopathol"},{"key":"2219_CR10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","volume":"181","author":"JJ Scarisbrick","year":"2019","unstructured":"Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181:350\u20137.","journal-title":"Br J Dermatol"},{"key":"2219_CR11","doi-asserted-by":"crossref","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713\u20131722. Erratum in: Blood. 2008;111:4830.","DOI":"10.1182\/blood-2008-02-142653"},{"key":"2219_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2219_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/cco.2018.11.03","volume":"8","author":"ML Lovgren","year":"2019","unstructured":"Lovgren ML, Scarisbrick JJ. Update on skin directed therapies in mycosis fungoides. Chin Clin Oncol. 2019;8(1):7.","journal-title":"Chin Clin Oncol"},{"key":"2219_CR14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180:496\u2013526.","journal-title":"Br J Dermatol"},{"key":"2219_CR15","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Primary cutaneous lymphoma. Version 1.2022. 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx. Accessed 9 Feb 2022."},{"key":"2219_CR16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archderm.1984.01650480047016","volume":"120","author":"DL Ramsay","year":"1984","unstructured":"Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Arch Dermatol. 1984;120:1585\u201390.","journal-title":"Arch Dermatol"},{"key":"2219_CR17","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","volume":"5","author":"RT Hoppe","year":"1987","unstructured":"Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987;5:1796\u2013803.","journal-title":"J Clin Oncol"},{"key":"2219_CR18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","volume":"19","author":"DL Ramsay","year":"1988","unstructured":"Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19:684\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"2219_CR19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","volume":"20","author":"EC Vonderheid","year":"1989","unstructured":"Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T\u00a0cell lymphoma. J Am Acad Dermatol. 1989;20:416\u201328.","journal-title":"J Am Acad Dermatol"},{"key":"2219_CR20","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(19831215)52:12<2214::AID-CNCR2820521207>3.0.CO;2-H","volume":"52","author":"NM Price","year":"1983","unstructured":"Price NM, Hoppe RT, Deneau DG. Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer. 1983;52:2214\u20139.","journal-title":"Cancer"},{"key":"2219_CR21","first-page":"165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165\u201373.","journal-title":"Arch Dermatol"},{"key":"2219_CR22","unstructured":"Valchlor (mechlorethamine gel) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed 9 Feb 2022."},{"key":"2219_CR23","unstructured":"Ledaga [prescribing information]. Jerusalem, Israel: Rafa Laboratories Ltd.; 2020. https:\/\/mohpublic.z6.web.core.windows.net\/IsraelDrugs\/Rishum_17_462433720.pdf. Accessed 9 Feb 2022."},{"key":"2219_CR24","unstructured":"Ledaga [summary of product characteristics]. Dublin, Ireland: Helsinn Birex Pharmaceuticals Ltd.; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ledaga-epar-product-information_en.pdf. Accessed 9 Feb 2022."},{"key":"2219_CR25","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jid.2021.08.137","volume":"141","author":"C Giuliano","year":"2021","unstructured":"Giuliano C, Frizzarin S, Beuttel C, et al. Percutaneous absorption of chlormethine gel in human skin: in vitro permeation testing. J Invest Dermatol. 2021;141:S171 (Abstract 134).","journal-title":"J Invest Dermatol"},{"key":"2219_CR26","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","volume":"141","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Geskin LJ, Kim EJ, et al. Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma. J Invest Dermatol. 2021;141:1601-1604.e2.","journal-title":"J Invest Dermatol"},{"key":"2219_CR27","unstructured":"Helsinn Therapeutics (U.S.) Inc. Getting started with VALCHLOR. 2022. https:\/\/www.valchlor.com\/getting-started-with-valchlor. Accessed 15 March 2022."},{"key":"2219_CR28","first-page":"155","volume":"25","author":"L Molin","year":"1980","unstructured":"Molin L, Thomsen K, Volden G, et al. Aspects of the treatment of mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Study Group. Cutis. 1980;25:155\u20137 (160\u2013161).","journal-title":"Cutis"},{"issue":"2","key":"2219_CR29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","volume":"27","author":"LM Lindahl","year":"2013","unstructured":"Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis. J Eur Acad Dermatol Venereol. 2013;27(2):163\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2219_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/cco.2018.10.01","volume":"8","author":"T Jennings","year":"2019","unstructured":"Jennings T, Duffy R, Gochoco A, et al. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. Chin Clin Oncol. 2019;8:13.","journal-title":"Chin Clin Oncol"},{"key":"2219_CR31","unstructured":"National Institutes of Health. National Library of Medicine. National Center for Biotechnology Information. Mechlorethamine. PubChem CID 4033. 2022. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/4033. Accessed 9 Feb 2022."},{"key":"2219_CR32","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(21)00645-6","volume":"156","author":"YT Chang","year":"2021","unstructured":"Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E. Increased chlormethine-induced DNA double stranded breaks in malignant T\u00a0cells from mycosis fungoides skin lesions. Eur J Cancer. 2021;156:S11.","journal-title":"Eur J Cancer"},{"key":"2219_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25\u201332.","journal-title":"JAMA Dermatol"},{"key":"2219_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clml.2020.11.022","volume":"21","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Kim EJ, Angello JT, Kim YH. Evaluating the treatment patterns of chlormethine\/mechlorethamine gel in patients with stage\u00a0I-IIA mycosis fungoides: by-time reanalysis of a randomized controlled phase 2 study. Clin Lymphoma Myeloma Leuk. 2021;21:119-124.e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2219_CR35","doi-asserted-by":"crossref","unstructured":"Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage\u00a0IA\u2013IIA mycosis fungoides. Dermatology. 2022;238(2):347\u201357.","DOI":"10.1159\/000516138"},{"key":"2219_CR36","doi-asserted-by":"publisher","unstructured":"Querfeld C, Kim YH, Guitart J, Scarisbrick J, Quaglino P. Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.896.","DOI":"10.1016\/j.jaad.2021.06.896"},{"key":"2219_CR37","doi-asserted-by":"publisher","unstructured":"Querfeld C, Scarisbrick JJ, Assaf C, et al. Chlormethine gel versus chlormethine ointment for treatment of patients with mycosis fungoides: a post hoc analysis of clinical trial data. Am J Clin Dermatol. 2022. https:\/\/doi.org\/10.1007\/s40257-022-00687-y.","DOI":"10.1007\/s40257-022-00687-y"},{"key":"2219_CR38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22:407\u201314.","journal-title":"Am J Clin Dermatol"},{"key":"2219_CR39","doi-asserted-by":"publisher","unstructured":"Prag Naveh H, Amitay-Laish I, Zidan O, et al. Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects. J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1967266.","DOI":"10.1080\/09546634.2021.1967266"},{"key":"2219_CR40","doi-asserted-by":"publisher","unstructured":"Papadavid E, Koumourtzis M, Nikolaou V, et al. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol. 2022. https:\/\/doi.org\/10.1111\/jdv.18183.","DOI":"10.1111\/jdv.18183"},{"key":"2219_CR41","doi-asserted-by":"publisher","unstructured":"Correia E, Krishasamy S, Suriano JG, et al. Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single center retrospective study. Clin Lymphoma Myeloma Leuk. 2022. https:\/\/doi.org\/10.1016\/j.clml.2022.02.002.","DOI":"10.1016\/j.clml.2022.02.002"},{"key":"2219_CR42","first-page":"1057","volume":"19","author":"U Wehkamp","year":"2021","unstructured":"Wehkamp U, Jost M, Gosmann J, Grote U, Bernard M, Stadler R. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges. 2021;19:1057\u201360.","journal-title":"J Dtsch Dermatol Ges"},{"key":"2219_CR43","first-page":"252","volume":"39","author":"F Dugre","year":"2017","unstructured":"Dugre F, Lefebure A, Martelli S, Pin M, Maubec E, Arnaud F. Chlormethine gel: effectiveness and tolerance to treat mycosis fungoides. Int J Clin Pharm. 2017;39:252 (Abstract DI006).","journal-title":"Int J Clin Pharm"},{"key":"2219_CR44","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0959-8049(21)00742-5","volume":"156","author":"P Sidiropoulou","year":"2021","unstructured":"Sidiropoulou P, Marinos L, Gerochristou M, et al. Topical mechlorethamine in mycosis fungoides: a prospective clinical, histopathological, and molecular analysis of 13 cases. Eur J Cancer. 2021;156:S61\u20132.","journal-title":"Eur J Cancer"},{"key":"2219_CR45","doi-asserted-by":"publisher","unstructured":"Koumourtzis M, Lampadaki K, Dalamaga M, Papadavid E. Chlormethine gel is efficient and safe in mycosis fungoides skin lesions. Acta Derm Venereol. 2022. https:\/\/doi.org\/10.2340\/actadv.v102.1095.","DOI":"10.2340\/actadv.v102.1095"},{"key":"2219_CR46","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/1346-8138.15276","volume":"47","author":"MH Trager","year":"2020","unstructured":"Trager MH, Chen C, Husain S, Geskin LJ. Nitrogen mustard gel-induced inflammation triggers lymphomatoid papulosis in patients with mycosis fungoides. J Dermatol. 2020;47:546\u201350.","journal-title":"J Dermatol"},{"key":"2219_CR47","doi-asserted-by":"crossref","unstructured":"Garcia-Saleem TJ, Stonesifer CJ, Khaleel AE, Geskin LJ. Management of mycosis fungoides with topical chlormethine\/mechlorethamine gel: a Columbia University Cutaneous Lymphoma Center experience. Acta Derm Venereol. 2021;101:adv00544.","DOI":"10.2340\/00015555-3911"},{"key":"2219_CR48","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1188\/15.CJON.E131-E139","volume":"19","author":"AB Chase","year":"2015","unstructured":"Chase AB, Markel K, Tawa MC. Optimizing care and compliance for the treatment of mycosis fungoides cutaneous T-cell lymphoma with mechlorethamine gel. Clin J Oncol Nurs. 2015;19:E131\u20139.","journal-title":"Clin J Oncol Nurs"},{"key":"2219_CR49","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","volume":"38","author":"K Lampadaki","year":"2021","unstructured":"Lampadaki K, Koumourtzis M, Karagianni F, Marinos L, Papadavid E. Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T\u00a0cell lymphoma: three case reports. Adv Ther. 2021;38:3455\u201364.","journal-title":"Adv Ther"},{"key":"2219_CR50","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.annder.2018.12.001","volume":"146","author":"C Gary","year":"2019","unstructured":"Gary C, Gautier V, Lazareth I, Bagot M, Asgari R. Necrotic leg ulcers after topical application of chlormethine. Ann Dermatol Venereol. 2019;146:226\u201331.","journal-title":"Ann Dermatol Venereol"},{"key":"2219_CR51","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1111\/jdv.15429","volume":"33","author":"J El Alami","year":"2019","unstructured":"El Alami J, Le Corre Y, Battistella M, et al. Mycosis fungoides presenting as vulvar plaques. J Eur Acad Dermatol Venereol. 2019;33:e172\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2219_CR52","doi-asserted-by":"crossref","unstructured":"Kim YH, Duvic M, Guitart J, Lessin S. Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%. J Clin Oncol. 2014;32 (abstract 9093).","DOI":"10.1200\/jco.2014.32.15_suppl.9093"},{"key":"2219_CR53","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0959-8049(21)00709-7","volume":"156","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Turini M, Gor D, Angello JT, Pashos C, Kim EJ. Concomitant use of steroids or phototherapy with chlormethine gel among patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study. Eur J Cancer. 2021;156:S44\u20135.","journal-title":"Eur J Cancer"},{"key":"2219_CR54","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/S0959-8049(21)00710-3","volume":"156","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Turini M, Gor D, Angello JT, Pashos C, Kim EJ. Maintenance therapy with chlormethine gel among patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study. Eur J Cancer. 2021;156:S45. https:\/\/doi.org\/10.1016\/S0959-8049(21)00710-3.","journal-title":"Eur J Cancer"},{"key":"2219_CR55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijd.IJD_433_18","volume":"65","author":"R Duffy","year":"2020","unstructured":"Duffy R, Jennings T, Sahu J. Mechlorethamine gel usage in patients with mycosis fungoides in a lymphoma clinic. Indian J Dermatol. 2020;65:237\u20139.","journal-title":"Indian J Dermatol"},{"key":"2219_CR56","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","volume":"11","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine gel for the treatment of skin lesions in all stages\u00a0of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Ther (Heidelb). 2021;11:1085\u2013106.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2219_CR57","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","volume":"83","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Geskin L, Guitart J, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study. J Am Acad Dermatol. 2020;83:928\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"2219_CR58","unstructured":"Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Incidence and types of contact dermatitis after chlormethine gel treatment in patients with mycosis fungoides-type cutaneous T-cell lymphoma: the MIDAS study. Presented at the 4th world congress of cutaneous lymphomas; 12\u201314 February 2020; Barcelona, Spain. Abstract Y-04."},{"key":"2219_CR59","first-page":"37","volume":"5","author":"E Kim","year":"2020","unstructured":"Kim E, Gilmore ES, Poligone B, Querfeld C. Chlormethine gel for mycosis fungoides T-cell lymphoma: recent real-world data. Eur Med J. 2020;5:37\u201341.","journal-title":"Eur Med J"},{"key":"2219_CR60","doi-asserted-by":"publisher","unstructured":"Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized Mechlorethamine\/Chlormethine Induced Dermatitis Assessment Study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides. Dermatol Ther (Heidelb). 2022. https:\/\/doi.org\/10.1007\/s13555-022-00681-6.","DOI":"10.1007\/s13555-022-00681-6"},{"key":"2219_CR61","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","volume":"6","author":"ES Gilmore","year":"2020","unstructured":"Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6:878\u201381.","journal-title":"JAAD Case Rep"},{"key":"2219_CR62","volume":"2","author":"YT Chang","year":"2021","unstructured":"Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E. Increased chlormethine-induced DNA double-stranded breaks in malignant T\u00a0cells from mycosis fungoides skin lesions. JID Innov. 2021;2: 100069.","journal-title":"JID Innov"},{"key":"2219_CR63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2020.04.049","volume":"83","author":"JA Zic","year":"2020","unstructured":"Zic JA, Ai W, Akilov OE, et al. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:703\u20134.","journal-title":"J Am Acad Dermatol"}],"updated-by":[{"DOI":"10.1007\/s12325-022-02403-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02219-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T18:29:56Z","timestamp":1674844196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02219-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02219-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-022-02403-y","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-022-02403-y","URL":"https:\/\/doi.org\/10.1007\/s12325-022-02403-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}